Skip to content

Study · Randomized controlled trial · n = 59 · 2016

8 results

Differential Effects of Teriparatide and Zoledronic Acid on Bone Mineralization Density Distribution at 6 and 24 Months in the SHOTZ Study.

Dempster DW, Roschger P, Misof BM, Zhou H, Paschalis EP, Alam J, Ruff VA, Klaushofer K, Taylor KA

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research30 Mar 2016Cited by 35 (Europe PMC)

PMID26931279 (opens in a new tab)DOI10.1002/jbmr.2825 (opens in a new tab)PepBankPUB-26931279
Publisher pagePubMedAsk about this study
Jump to 8 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. 8 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In women with osteoporosis, cancellous mean mineralization was lower with teriparatide than zoledronic acid at 6 months.

    In plain wordsIn women with osteoporosis, cancellous bone had less mineralization with teriparatide than zoledronic acid at 6 months.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    DecreaseCancellous mean mineralization at 6 months
    Study

    n = 59

    Comparator
    zoledronic acid
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20 μg/d · subcutaneous injection · 6 monthsAs given in this study (human).

    Measurements

    CaMEAN difference, ZOL higher than teriparatide
    2.2%
    cancellous bone at 6 months

    Source sentences

    Summary
    In cancellous bone, ZOL treatment was associated at 6 and 24 months with significantly higher average degree of mineralization (CaMEAN, +2.2%, p = 0.018; +3.9%, p = 0.009, respectively)
    5 context sentences
    Summary · context
    indicating higher mineralization density and more homogeneous mineral content versus TPTD.
    Summary · context
    The Skeletal Histomorphometry in Patients on Teriparatide or Zoledronic Acid Therapy (SHOTZ) study assessed the progressive effects of teriparatide (TPTD) and zoledronic acid (ZOL) on bone remodeling and material properties in postmenopausal women with osteoporosis.
    Summary · context
    The 12-month primary study was randomized and double blind until the month 6 biopsy, then open label.
    Summary · context
    Patients (TPTD, n = 28; ZOL, n = 31) were then eligible to enter a 12-month open-label extension with their original treatment: TPTD 20 μg/d (subcutaneous injection) or ZOL 5 mg/yr (intravenous infusion).
    Summary · context
    A second biopsy was collected from the contralateral side at month 24 (TPTD, n = 10; ZOL, n = 10).
  2. 02HumanRandomized controlled trialEfficacy outcome

    In women with osteoporosis, cancellous low mineralized area was higher with teriparatide than zoledronic acid at 6 months.

    In plain wordsIn women with osteoporosis, teriparatide produced more low mineralized cancellous bone than zoledronic acid at 6 months.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseCancellous low mineralized area at 6 months
    Study

    n = 59

    Comparator
    zoledronic acid
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20 μg/d · subcutaneous injection · 6 monthsAs given in this study (human).

    Measurements

    CaLOW difference, zoledronic acid versus teriparatide
    −34.6%
    cancellous bone, 6 months, lower with zoledronic acid

    Source sentences

    Summary
    and with lower percentage of low mineralized areas (CaLOW , -34.6%, p = 0.029; -33.7%, p = 0.025, respectively)
    5 context sentences
    Summary · context
    indicating higher mineralization density and more homogeneous mineral content versus TPTD.
    Summary · context
    The Skeletal Histomorphometry in Patients on Teriparatide or Zoledronic Acid Therapy (SHOTZ) study assessed the progressive effects of teriparatide (TPTD) and zoledronic acid (ZOL) on bone remodeling and material properties in postmenopausal women with osteoporosis.
    Summary · context
    The 12-month primary study was randomized and double blind until the month 6 biopsy, then open label.
    Summary · context
    Patients (TPTD, n = 28; ZOL, n = 31) were then eligible to enter a 12-month open-label extension with their original treatment: TPTD 20 μg/d (subcutaneous injection) or ZOL 5 mg/yr (intravenous infusion).
    Summary · context
    A second biopsy was collected from the contralateral side at month 24 (TPTD, n = 10; ZOL, n = 10).
  3. 03HumanRandomized controlled trialEfficacy outcome

    In women with osteoporosis, cancellous mineralization was more heterogeneous with teriparatide than zoledronic acid at 6 months.

    In plain wordsIn women with osteoporosis, cancellous bone mineralization was more varied with teriparatide than zoledronic acid at 6 months.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseCancellous mineralization heterogeneity at 6 months
    Study

    n = 59

    Comparator
    zoledronic acid
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20 μg/d · subcutaneous injection · 6 monthsAs given in this study (human).

    Measurements

    CaWIDTH difference, zoledronic acid versus teriparatide
    −12.3%
    cancellous bone, 6 months, lower with zoledronic acid

    Source sentences

    Summary
    and heterogeneity of mineralization CaWIDTH (-12.3%, p = 0.003; -9.9%, p = 0.012, respectively), indicating higher mineralization density and more homogeneous mineral content versus TPTD.
    4 context sentences
    Summary · context
    The Skeletal Histomorphometry in Patients on Teriparatide or Zoledronic Acid Therapy (SHOTZ) study assessed the progressive effects of teriparatide (TPTD) and zoledronic acid (ZOL) on bone remodeling and material properties in postmenopausal women with osteoporosis.
    Summary · context
    The 12-month primary study was randomized and double blind until the month 6 biopsy, then open label.
    Summary · context
    Patients (TPTD, n = 28; ZOL, n = 31) were then eligible to enter a 12-month open-label extension with their original treatment: TPTD 20 μg/d (subcutaneous injection) or ZOL 5 mg/yr (intravenous infusion).
    Summary · context
    A second biopsy was collected from the contralateral side at month 24 (TPTD, n = 10; ZOL, n = 10).
  4. 04HumanRandomized controlled trialEfficacy outcome

    In women with osteoporosis, cancellous mean mineralization was lower with teriparatide than zoledronic acid at 24 months.

    In plain wordsIn women with osteoporosis, cancellous bone had less mineralization with teriparatide than zoledronic acid at 24 months.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    DecreaseCancellous mean mineralization at 24 months
    Study

    n = 20

    Comparator
    zoledronic acid
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20 μg/d · subcutaneous injection · 24 monthsAs given in this study (human).

    Measurements

    CaMEAN difference, zoledronic acid versus teriparatide
    3.9%
    cancellous bone, 24 months, higher with zoledronic acid

    Source sentences

    Summary
    In cancellous bone, ZOL treatment was associated at 6 and 24 months with significantly higher average degree of mineralization (CaMEAN, +2.2%, p = 0.018; +3.9%, p = 0.009, respectively)
    5 context sentences
    Summary · context
    indicating higher mineralization density and more homogeneous mineral content versus TPTD.
    Summary · context
    The Skeletal Histomorphometry in Patients on Teriparatide or Zoledronic Acid Therapy (SHOTZ) study assessed the progressive effects of teriparatide (TPTD) and zoledronic acid (ZOL) on bone remodeling and material properties in postmenopausal women with osteoporosis.
    Summary · context
    The 12-month primary study was randomized and double blind until the month 6 biopsy, then open label.
    Summary · context
    Patients (TPTD, n = 28; ZOL, n = 31) were then eligible to enter a 12-month open-label extension with their original treatment: TPTD 20 μg/d (subcutaneous injection) or ZOL 5 mg/yr (intravenous infusion).
    Summary · context
    A second biopsy was collected from the contralateral side at month 24 (TPTD, n = 10; ZOL, n = 10).
  5. 05HumanRandomized controlled trialEfficacy outcome

    In women with osteoporosis, cancellous low mineralized area was higher with teriparatide than zoledronic acid at 24 months.

    In plain wordsIn women with osteoporosis, teriparatide produced more low mineralized cancellous bone than zoledronic acid at 24 months.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseCancellous low mineralized area at 24 months
    Study

    n = 20

    Comparator
    zoledronic acid
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20 μg/d · subcutaneous injection · 24 monthsAs given in this study (human).

    Measurements

    CaLOW difference, zoledronic acid versus teriparatide
    −33.7%
    cancellous bone, 24 months, lower with zoledronic acid

    Source sentences

    Summary
    and with lower percentage of low mineralized areas (CaLOW , -34.6%, p = 0.029; -33.7%, p = 0.025, respectively)
    5 context sentences
    Summary · context
    indicating higher mineralization density and more homogeneous mineral content versus TPTD.
    Summary · context
    The Skeletal Histomorphometry in Patients on Teriparatide or Zoledronic Acid Therapy (SHOTZ) study assessed the progressive effects of teriparatide (TPTD) and zoledronic acid (ZOL) on bone remodeling and material properties in postmenopausal women with osteoporosis.
    Summary · context
    The 12-month primary study was randomized and double blind until the month 6 biopsy, then open label.
    Summary · context
    Patients (TPTD, n = 28; ZOL, n = 31) were then eligible to enter a 12-month open-label extension with their original treatment: TPTD 20 μg/d (subcutaneous injection) or ZOL 5 mg/yr (intravenous infusion).
    Summary · context
    A second biopsy was collected from the contralateral side at month 24 (TPTD, n = 10; ZOL, n = 10).
  6. 06HumanRandomized controlled trialEfficacy outcome

    In women with osteoporosis, cancellous mineralization was more heterogeneous with teriparatide than zoledronic acid at 24 months.

    In plain wordsIn women with osteoporosis, cancellous bone mineralization was more varied with teriparatide than zoledronic acid at 24 months.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseCancellous mineralization heterogeneity at 24 months
    Study

    n = 20

    Comparator
    zoledronic acid
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20 μg/d · subcutaneous injection · 24 monthsAs given in this study (human).

    Measurements

    CaWIDTH difference, zoledronic acid versus teriparatide
    −9.9%
    cancellous bone, 24 months, lower with zoledronic acid

    Source sentences

    Summary
    and heterogeneity of mineralization CaWIDTH (-12.3%, p = 0.003; -9.9%, p = 0.012, respectively), indicating higher mineralization density and more homogeneous mineral content versus TPTD.
    4 context sentences
    Summary · context
    The Skeletal Histomorphometry in Patients on Teriparatide or Zoledronic Acid Therapy (SHOTZ) study assessed the progressive effects of teriparatide (TPTD) and zoledronic acid (ZOL) on bone remodeling and material properties in postmenopausal women with osteoporosis.
    Summary · context
    The 12-month primary study was randomized and double blind until the month 6 biopsy, then open label.
    Summary · context
    Patients (TPTD, n = 28; ZOL, n = 31) were then eligible to enter a 12-month open-label extension with their original treatment: TPTD 20 μg/d (subcutaneous injection) or ZOL 5 mg/yr (intravenous infusion).
    Summary · context
    A second biopsy was collected from the contralateral side at month 24 (TPTD, n = 10; ZOL, n = 10).
  7. 07HumanRandomized controlled trialEfficacy outcome

    In women with osteoporosis, mineralization density did not increase over time with teriparatide.

    In plain wordsIn women with osteoporosis, bone mineralization density did not increase over time with teriparatide.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    No significant changeMineralization density over time
    Study

    n = 10

    Comparator
    month 6
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20 μg/d · subcutaneous injection · 24 monthsAs given in this study (human).

    Source sentences

    Summary
    In sharp contrast, mineralization density did not increase over time with TPTD, reflecting ongoing deposition of new bone.
    4 context sentences
    Summary · context
    The Skeletal Histomorphometry in Patients on Teriparatide or Zoledronic Acid Therapy (SHOTZ) study assessed the progressive effects of teriparatide (TPTD) and zoledronic acid (ZOL) on bone remodeling and material properties in postmenopausal women with osteoporosis.
    Summary · context
    The 12-month primary study was randomized and double blind until the month 6 biopsy, then open label.
    Summary · context
    Patients (TPTD, n = 28; ZOL, n = 31) were then eligible to enter a 12-month open-label extension with their original treatment: TPTD 20 μg/d (subcutaneous injection) or ZOL 5 mg/yr (intravenous infusion).
    Summary · context
    A second biopsy was collected from the contralateral side at month 24 (TPTD, n = 10; ZOL, n = 10).
  8. 08HumanRandomized controlled trialEfficacy outcome

    In women with osteoporosis, cortical mineralization showed results similar to the cancellous comparison between teriparatide and zoledronic acid.

    In plain wordsIn women with osteoporosis, cortical bone showed a similar mineralization pattern to the cancellous comparison between teriparatide and zoledronic acid.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    MixedCortical bone mineralization pattern
    Study

    n: not reported in source

    Comparator
    zoledronic acid
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20 μg/d · subcutaneous injectionAs given in this study (human).

    Source sentences

    Summary
    Similar results were observed in cortical bone.
    5 context sentences
    Summary · context
    indicating higher mineralization density and more homogeneous mineral content versus TPTD.
    Summary · context
    The Skeletal Histomorphometry in Patients on Teriparatide or Zoledronic Acid Therapy (SHOTZ) study assessed the progressive effects of teriparatide (TPTD) and zoledronic acid (ZOL) on bone remodeling and material properties in postmenopausal women with osteoporosis.
    Summary · context
    The 12-month primary study was randomized and double blind until the month 6 biopsy, then open label.
    Summary · context
    Patients (TPTD, n = 28; ZOL, n = 31) were then eligible to enter a 12-month open-label extension with their original treatment: TPTD 20 μg/d (subcutaneous injection) or ZOL 5 mg/yr (intravenous infusion).
    Summary · context
    A second biopsy was collected from the contralateral side at month 24 (TPTD, n = 10; ZOL, n = 10).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.